Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsCefotaxime1-2g IV Q24HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
45560115370.15-0.552.5-6039-60 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Chodos J, Franck E, Saltzman M, Neu H. Pharmacokinetics of Intravenous Cefotaxime in Patients Undergoing Chronic Hemodialysis. Therapeutic Drug Monitoring 1981; 3, 71-4.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00493
  • Glöckner W, Höffler U, Kindler J, Peters G, Sieberth H. Elimination kinetics of cefotaxime in patients with renal insufficiency requiring dialysis. The Journal of antimicrobial chemotherapy 1980; 6 (Suppl A), 219-23.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Ings R, Fillastre J, Godin M, Leroy A, Humbert G. The Pharmacokinetics of Cefotaxime and Its Metabolites in Subjects with Normal and Impaired Renal Function. Reviews Of Infectious Diseases 1982; 4(Supplement), 379-91.
  • Matzke G, Abraham P, Halstenson C, Keane W. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clinical pharmacology and therapeutics 1985; 38(1), 31-6.